ArticleAdvances in therapy2026
Treatment Patterns and Clinical Outcomes in Unresectable Stage III EGFR-Mutated Non-Small Cell Lung Cancer in China.
Article in Advances in therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03521154 (A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter, International Study of Osimertinib as Maintenance Therapy in Patients With Locally Advanced, Unresectable EGFR Mutation-positive Non-Small Cell Lung Cancer), which is not on this map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter, International Study of Osimertinib as Maintenance Therapy in Patients With Locally Advanced, Unresectable EGFR Mutation-positive Non-Small Cell Lung Cancer (Stage III) Whose Disease Has Not Progressed Following Definitive Platinum-based Chemoradiation Therapy (LAURA).
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Optimal treatment strategies for unresectable stage IIIFrontiers in oncology · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionFollowing the LAURA study (NCT03521154), the third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) osimertinib was approved for unresectable stage III EGFR-mutated non-small cell lung cancer (NSCLC) after chemoradiotherapy. To inform clinical decision-making, we report real-world (rw) treatment patterns and outcomes in Chinese patients with unresectable stage III EGFR-mutated NSCLC who underwent chemoradiotherapy.
methodsData were retrospectively extracted from the China Multicentre Lung Cancer Precision Medicine Registry medical records of adults with unresectable stage III EGFR-mutated (exon 19 deletion [Ex19del]/leucine-to-arginine substitution at position 858 [L858R]) NSCLC (diagnosed Jan 2016-Dec 2019) who received standard-of-care chemoradiotherapy. The primary outcome was rw progression-free survival (rwPFS) and secondary outcomes were mutation testing patterns, treatment sequencing post-diagnosis, and rw time-to-next treatment or death (rwTTNTD).
resultsOf 51 patients, 65%/33% had Ex19del/L858R mutations. As first treatment, 31 patients (61%) received chemoradiotherapy plus EGFR-TKI (mainly first-generation) and 20 (39%) chemoradiotherapy alone. Of 34 (67%) patients who received first-subsequent treatment, most were given EGFR-TKI (88%). In patients who received chemoradiotherapy plus EGFR-TKIs (first-generation) or chemoradiotherapy alone, median (95% confidence interval) rwPFS/rwTTNTD was 22.6 (14.2-34.6)/25.0 (21.5-44.7) or 12.2 (10.5-not estimable)/13.6 (10.5-not estimable) months, respectively.
conclusionThese rw results show that while first-generation EGFR-TKIs are associated with numerically longer rwPFS and rwTTNTD relative to chemoradiotherapy alone in Chinese patients with unresectable stage III EGFR-mutated NSCLC, there remains an unmet need to prolong survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.